India, April 15 -- Traws Pharma Inc. (TRAW) announced a private investment in public equity ("PIPE") financing that could bring up to $60 million, aimed at supporting its influenza program through planned human challenge trial in the United Kingdom.
The financing, completed on April 15, 2026, provides an initial $10 million in gross proceeds at closing. Shares were sold at $1.6730 each, with investors also receiving milestone-based and three-year warrants that could deliver up to $50 million in additional funding if fully exercised.
The structure includes:
-Series A warrant: up to $10.0 million upon approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to conduct the challenge trial.
-Series B warrant: up to ...